Residency · Residency · Radiation Oncology

The Four Rs of Radiobiology

Overview

The biological rationale for fractionated radiotherapy is founded on four fundamental processes: Repair, Redistribution, Repopulation, and Reoxygenation. These "4 Rs," first described by Withers in 1975, explain why delivering radiation in multiple small fractions over time maximizes the therapeutic ratio compared to administering a single large dose. Occasionally, a fifth R—Radiosensitivity (intrinsic)—is added to acknowledge the inherent variation in radiation sensitivity among tumors and normal tissues.

Repair of Sublethal Damage

Concept

Sublethal damage (SLD) refers to radiation-induced damage that is not lethal by itself but can become lethal if additional damage accumulates before repair occurs. Between radiation fractions, cells repair this sublethal damage, thereby restoring their radiation tolerance. Normal tissues generally repair sublethal damage more efficiently than tumor cells, which underlies the therapeutic advantage of fractionation.

Kinetics

The repair half-time for sublethal damage is approximately 0.5 to 2 hours for most tissues. By six hours, about 95% of reparable damage is typically repaired. However, tissues such as the spinal cord and brain may have longer repair half-times, around four hours, which justifies minimum interfraction intervals of eight hours for targets adjacent to the central nervous system. Repair kinetics are often modeled as mono-exponential or bi-exponential decay of sublethal damage.

Clinical Implications

A minimum interfraction interval of six hours (or eight hours for CNS-related treatments) is essential when delivering twice-daily fractions. Shorter intervals risk incomplete repair, increasing normal tissue toxicity without a proportional increase in tumor control. The survival curve shoulder, which reflects repair capacity, is effectively re-expressed with each fraction. Tissues with large repair capacity, characterized by a low alpha/beta ratio and a large shoulder on the survival curve, benefit most from fractionation. This explains why late-responding normal tissues are preferentially spared by using smaller fraction sizes.

Potentially Lethal Damage Repair (PLDR)

Potentially lethal damage (PLD) is damage that would normally be lethal but can be repaired if cells are maintained in non-proliferating conditions after irradiation. Clinically, slowly growing tumors or quiescent cells in the G0 phase may repair potentially lethal damage between fractions. Some tumors, such as melanoma and renal cell carcinoma, were historically thought to exhibit enhanced PLDR, but this concept has largely been replaced by other explanations for their apparent radioresistance.

Redistribution (Reassortment)

Cell Cycle Radiosensitivity

Cells exhibit varying radiosensitivity depending on their position in the cell cycle. The most radiosensitive phases are late G2 and M phase, while cells in late S phase are the most resistant. Cells in G1 phase have intermediate sensitivity, which can depend on the status of the tumor suppressor p53. The variation in radiosensitivity across the cell cycle can be as much as threefold.

Redistribution After Irradiation

A single radiation dose preferentially kills cells in the sensitive phases, leaving a surviving population enriched in resistant phases, particularly late S phase. Between fractions, surviving cells progress through the cell cycle and redistribute into more radiosensitive phases. By the time the next fraction is delivered, the cell population has a more representative distribution of cell cycle phases, including those that are sensitive. This process is sometimes called "reassortment" or "self-sensitization."

Clinical Implications

Redistribution contributes significantly to the effectiveness of fractionated radiotherapy, especially for rapidly cycling tumors. Tumors with rapid cell cycling benefit more from redistribution than slowly growing tumors. This effect is most pronounced during the first few fractions, with subsequent fractions continuing to exploit redistribution. Additionally, drugs that synchronize cells in sensitive phases, such as taxanes which arrest cells in G2/M, can act as radiosensitizers by leveraging this principle.

Repopulation

Tumor Repopulation

During a fractionated course of radiation, surviving tumor cells continue to proliferate. After an initial lag period, surviving clonogenic cells may accelerate their proliferation, a phenomenon known as accelerated repopulation. In head and neck squamous cell carcinoma, accelerated repopulation typically begins around three to four weeks (days 21–28) after the start of treatment. The potential doubling time during this accelerated phase may be as short as three to five days. Each day of treatment prolongation beyond the planned duration reduces tumor control by approximately 0.6 to 1.4% in rapidly proliferating tumors.

Normal Tissue Repopulation

Acute-responding tissues such as mucosa, skin, and bone marrow also repopulate during treatment. This repopulation mitigates acute toxicity and allows treatment to continue. Planned treatment breaks can facilitate healing of acute mucosal reactions but come at the cost of tumor repopulation. Late-responding tissues, however, do not meaningfully repopulate during treatment.

Clinical Implications

Treatment breaks should be avoided because unplanned interruptions are detrimental to local tumor control. Overall treatment time is particularly important for rapidly proliferating tumors such as head and neck squamous cell carcinoma, cervical cancer, and non-small cell lung cancer. Accelerated fractionation, which shortens overall treatment time, can counteract tumor repopulation. For example, the DAHANCA 6&7 trials demonstrated that delivering six fractions per week instead of five improved local control in head and neck cancer. The CHART regimen, delivering 54 Gy in 36 fractions over 12 days with continuous hyperfractionated accelerated radiotherapy, is another example used in lung cancer. Weekend breaks in the standard Monday-to-Friday schedule allow tumor repopulation on weekends, representing a compromise between biological considerations and logistical constraints. When comparing biologically effective doses (BED) across different schedules, treatment time correction should be applied to account for these effects.

Reoxygenation

Concept

Tumors consist of a mixture of well-oxygenated and hypoxic cells. Hypoxic cells are approximately 2.5 to 3 times more resistant to radiation than oxygenated cells. After a fraction of radiation, well-oxygenated cells are preferentially killed. Between fractions, previously hypoxic cells gain access to oxygen because killed tumor cells no longer consume oxygen, tumor shrinkage brings cells closer to blood vessels, and perfusion patterns change.

Kinetics of Reoxygenation

Reoxygenation begins within hours and may continue for days between fractions. The rate of reoxygenation varies among tumor types; some, such as squamous cell carcinomas, reoxygenate rapidly, while others, like sarcomas, do so more slowly. By the next fraction, a proportion of formerly hypoxic cells have become oxygenated and thus more radiosensitive. Over the entire course of fractionated radiotherapy, progressive reoxygenation reduces the effective hypoxic fraction.

Clinical Implications

Reoxygenation is one of the major advantages of fractionation compared to single-dose treatment. Rapid fractionation schedules, such as stereotactic body radiotherapy (SBRT), may not allow sufficient reoxygenation between fractions. However, very high single-fraction doses may overcome hypoxic resistance through sheer dose intensity. Tumors that reoxygenate poorly and remain persistently hypoxic tend to have worse outcomes. Strategies to address this include the use of hypoxic sensitizers, dose escalation, and high-linear energy transfer (LET) radiation.

Radiosensitivity (The "5th R")

Intrinsic Radiosensitivity

Cells and tissues vary in their inherent sensitivity to radiation, independent of the four Rs. This intrinsic radiosensitivity is determined by factors such as DNA repair capacity, apoptotic threshold, cell cycle checkpoint function, and other molecular characteristics. For example, lymphocytes and spermatogonia are highly radiosensitive, dying by interphase apoptosis at very low doses. Fibroblasts and endothelial cells have intermediate sensitivity, while mature neurons and muscle cells are highly radioresistant due to their non-dividing nature. Among tumors, lymphomas and seminomas are highly radiosensitive, whereas melanomas and sarcomas are classically considered radioresistant, although this is somewhat of an oversimplification.

Molecular Determinants

Molecular factors such as p53 status, ATM function, BRCA1/2 status, and the integrity of the Rb pathway influence intrinsic radiosensitivity. In the future, tumor molecular profiling may allow personalized fractionation prescriptions tailored to these characteristics.

Integration of the 4 Rs in Clinical Practice

Each of the four Rs influences tumor and normal tissue effects differently, shaping the net therapeutic outcome. Repair allows partial repair in tumors but excellent repair in normal tissues, favoring fractionation by sparing normal tissue. Redistribution sensitizes tumor cells by redistributing them into more radiosensitive phases, while it is less relevant for many normal tissues that are not actively cycling, thus favoring fractionation. Repopulation has a mixed effect: tumor repopulation is detrimental, whereas acute tissue repopulation is beneficial, which limits the overall treatment time. Reoxygenation sensitizes tumor cells by converting hypoxic cells into oxygenated ones, favoring fractionation without affecting normal tissues.

Overall, three of the four Rs—repair, redistribution, and reoxygenation—favor fractionation by improving the therapeutic ratio. Repopulation acts as a counterbalancing force that limits the overall treatment time. The optimal fractionation schedule balances all four Rs according to the clinical scenario.

<image>A four-panel illustration showing each of the 4 Rs. Panel 1 (Repair): a cell survival curve showing shoulder recovery between fractions, with the multi-fraction survival curve being steeper than the single-dose curve at the same total dose. Panel 2 (Redistribution): a circular cell cycle diagram with G1, S, G2, M phases labeled, showing cells killed preferentially in M and G2 after one fraction, then redistributing by the next fraction. Panel 3 (Repopulation): a graph showing tumor cell number over time during a 6-week course, with daily fractions reducing cell number but repopulation occurring between fractions and on weekends. Panel 4 (Reoxygenation): a tumor cross-section showing hypoxic cells becoming oxygenated as surrounding well-oxygenated cells are killed by radiation.</image>

<image>A clinical timeline diagram showing a 7-week course of head and neck radiation therapy. The x-axis is treatment days (1-49). Above the timeline, daily fractions are marked. Below, color-coded bars show the dominant biological processes at each phase: early fractions emphasize repair and redistribution, by week 3-4 accelerated repopulation begins (marked with a warning symbol), and reoxygenation gradually reduces the hypoxic fraction over the course. A callout box warns that treatment interruptions beyond day 28 are most damaging due to accelerated repopulation.</image>

Key Clinical Pearls

The four Rs collectively explain why delivering 30 fractions of 2 Gy is more effective and better tolerated than a single dose of 60 Gy. Repair spares late-responding normal tissues, redistribution and reoxygenation sensitize tumor cells, and repopulation of acute tissues allows treatment tolerance. Treatment prolongation is detrimental to tumor control in rapidly proliferating cancers, so every effort should be made to complete treatment on schedule. If breaks occur, compensatory measures such as extra fractions or weekend treatments should be considered. The minimum interfraction interval of six hours is not arbitrary; it is based on repair kinetics. Using intervals shorter than six hours (or eight hours for CNS targets) risks incomplete repair and excessive late toxicity. Radiosensitizers that exploit redistribution, such as taxanes causing G2/M arrest, or reoxygenation, such as nimorazole and carbogen, represent the most successful clinical applications of the four Rs. The efficacy of SBRT, despite bypassing some Rs like limited reoxygenation and no redistribution time, suggests additional mechanisms of cell kill at high doses per fraction, including vascular damage and immune activation.

References

• Withers HR. "The four R's of radiotherapy." Adv Radiat Biol. 1975;5:241-271.
• Steel GG, McMillan TJ, Peacock JH. "The 5Rs of radiobiology." Int J Radiat Biol. 1989;56(6):1045-1048.
• Thames HD, Hendry JH. Fractionation in Radiotherapy. Taylor & Francis, 1987.
• Withers HR et al. "The hazard of accelerated tumor clonogen repopulation during radiotherapy." Acta Oncol. 1988;27(2):131-146.
• Overgaard J et al. "Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial." Lancet. 2003;362:933-940.

Read this lecture as Markdown